Piper Sandler analyst Edward Tenthoff upgraded Fate Therapeutics (NASDAQ: FATE) from Neutral to Overweight with a price target of $6.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE